Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is withdrawing approval of six new drug applications (NDAs) from multiple holders of these applications. The basis for the withdrawals is that the holders of the applications have repeatedly failed to file required annual reports for the applications.
Effective October 10, 2007.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.End Further Info End Preamble Start Supplemental Information
The holders of approved applications to market new drugs for human use are required to submit annual reports to FDA concerning each of their approved applications in accordance with § 314.81 (21 CFR 314.81).
In the Federal Register of June 28, 2007 (72 FR 35498), FDA published a notice offering an opportunity for a hearing (NOOH) on a proposal to withdraw approval of six NDAs because the firms had failed to submit the required annual reports for these applications. The holders of these applications did not respond to the NOOH. Failure to file a written notice of participation and request for hearing as required by part 314 (21 CFR 314) in § 314.200 constitutes an election by the applicant not to make use of the opportunity for a hearing concerning the proposal to withdraw approval of the applications and a waiver of any contentions concerning the legal status of the drug products. Therefore, the Director, Center for Drug Evaluation and Research, is withdrawing approval of the six applications listed in the table of this document.
|NDA 6-410||Benzedrex (propylhexadrine) Nasal Spray||Menley & James Laboratories, Inc., Commonwealth Corporate Center, 100 Tournament Dr., Horsham, PA 19044|
|Start Printed Page 57587|
|NDA 7-518||Synthetic Vitamin A||Pfizer Laboratories, Division of Pfizer, Inc., 235 East 42nd St., New York, NY 10017|
|NDA 8-837||Isoniazid Tablets||Barnes Hind, 895 Kifer Rd., Sunnyvale, CA 94806|
|NDA 8-851||NDK Fluoride Dentifrice (sodium monofluorophosphate)||NDK Co., c/o J.W. Emmer/Kenneth Emmer, 215 Genevieve Dr., Lafayette, LA 70503|
|NDA 9-395||Paskalium (potassium aminosalicylate)||Glenwood, 111 Cedar Lane, Englewood, NJ 07631|
|NDA 19-518||Extra Strength Aim (sodium monofluorophosphate)||Chesebrough-Ponds USA Co., 33 Benedict Pl., P.O. Box 6000, Greenwich, CT 06836-6000|
The Director, Center for Drug Evaluation and Research, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), and under authority delegated by the Commissioner, finds that the holders of the applications listed in this document have repeatedly failed to submit reports required by § 314.81. In addition, under § 314.200, we find that the holders of the applications have waived any contentions concerning the legal status of the drug products. Therefore, under these findings, approval of the applications listed in this document, and all amendments and supplements thereto, is hereby withdrawn, effective October 10, 2007.Start Signature
Dated: September 24, 2007.
Douglas C. Throckmorton,
Deputy Director, Center for Drug Evaluation and Research.
[FR Doc. E7-19865 Filed 10-9-07; 8:45 am]
BILLING CODE 4160-01-S